VVOS

Vivos Therapeutics (VVOS)

Vivos Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:VVOS

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/15	05 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VVOS	Vivos Therapeutics Inc
2024/06/12	20 : 30	GlobeNewswire Inc.	Vivos Therapeutics Closes $7.5 Million At-The-Market Private Equity-Backed Investment and Launches Strategic Marketing and Distribution Alliance	NASDAQ:VVOS	Vivos Therapeutics Inc
2024/05/21	02 : 04	GlobeNewswire Inc.	Consolidated Water Comments on ISS and Glass Lewis Reports and Urges Stockholders to Vote “FOR” Re-Election of Its Highly Qualified Directors	NASDAQ:VVOS	Vivos Therapeutics Inc
2024/05/18	05 : 43	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VVOS	Vivos Therapeutics Inc
2024/05/16	03 : 54	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VVOS	Vivos Therapeutics Inc
2024/05/15	05 : 16	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:VVOS	Vivos Therapeutics Inc
2024/05/15	05 : 05	GlobeNewswire Inc.	Vivos Therapeutics Reports First Quarter 2024 Financial Results and Provides Operational Update	NASDAQ:VVOS	Vivos Therapeutics Inc
2024/05/14	20 : 30	GlobeNewswire Inc.	Vivos Therapeutics Schedules Release of First Quarter 2024 Financial Results and Conference Call	NASDAQ:VVOS	Vivos Therapeutics Inc
2024/04/09	20 : 30	GlobeNewswire Inc.	Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full Approval for Medicare Reimbursement	NASDAQ:VVOS	Vivos Therapeutics Inc
2024/03/29	05 : 05	GlobeNewswire Inc.	Vivos Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Operational Update	NASDAQ:VVOS	Vivos Therapeutics Inc
2024/03/28	20 : 30	GlobeNewswire Inc.	Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Conference Call	NASDAQ:VVOS	Vivos Therapeutics Inc
2024/02/15	22 : 55	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VVOS	Vivos Therapeutics Inc
2024/02/15	22 : 00	GlobeNewswire Inc.	Vivos Therapeutics Announces Exercise of Warrants for Approximately $4.0 Million Aggregate Gross Proceeds	NASDAQ:VVOS	Vivos Therapeutics Inc
2024/02/15	07 : 42	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:VVOS	Vivos Therapeutics Inc
2024/02/06	21 : 30	GlobeNewswire Inc.	Vivos Therapeutics Highlights Significant Favorable Market Developments Creating Exciting New Growth Opportunities	NASDAQ:VVOS	Vivos Therapeutics Inc
2024/01/08	21 : 30	GlobeNewswire Inc.	Vivos Therapeutics Sees Positive Preliminary Metrics Following Unprecedented FDA 510(k) Clearance of the Company’s Proprietary Oral Medical Devices to Treat Severe OSA	NASDAQ:VVOS	Vivos Therapeutics Inc
2023/12/11	21 : 30	GlobeNewswire Inc.	Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”	NASDAQ:VVOS	Vivos Therapeutics Inc
2023/12/04	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:VVOS	Vivos Therapeutics Inc
2023/12/02	06 : 12	Edgar (US Regulatory)	Form 424B1 - Prospectus [Rule 424(b)(1)]	NASDAQ:VVOS	Vivos Therapeutics Inc
2023/12/01	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VVOS	Vivos Therapeutics Inc
2023/12/01	06 : 03	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:VVOS	Vivos Therapeutics Inc
2023/11/29	21 : 30	GlobeNewswire Inc.	Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea	NASDAQ:VVOS	Vivos Therapeutics Inc
2023/11/23	06 : 46	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:VVOS	Vivos Therapeutics Inc
2023/11/15	06 : 05	GlobeNewswire Inc.	Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update	NASDAQ:VVOS	Vivos Therapeutics Inc
2023/11/10	06 : 30	GlobeNewswire Inc.	Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call	NASDAQ:VVOS	Vivos Therapeutics Inc
2023/11/04	06 : 00	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:VVOS	Vivos Therapeutics Inc
2023/11/03	06 : 10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VVOS	Vivos Therapeutics Inc
2023/11/03	06 : 00	GlobeNewswire Inc.	Vivos Therapeutics Closes $4 Million Private Placement	NASDAQ:VVOS	Vivos Therapeutics Inc
2023/10/31	21 : 00	GlobeNewswire Inc.	Vivos Therapeutics Announces Pricing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules	NASDAQ:VVOS	Vivos Therapeutics Inc
2023/10/28	05 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:VVOS	Vivos Therapeutics Inc